STARPHARMA HLDG.SP.ADR/10(PQ6A)

Description: Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

---

Keywords: Biopharmaceutical Solid Tumors Cancer Treatment Ovarian Cancer Antiseptics Treating Cancer Cancer Therapy Her2 Sexually Transmitted Diseases And Infections Probiotics Novel Cancer Gynaecological Cancer Docetaxel Bacterial Vaginosis Dendrimer Cabazitaxel Dendrimer Products Pancreatic And Other Cancers Dendrimer Technology Microbicides For Sexually Transmitted Infections Ovarian And Colorectal Cancer Ovarian Cancer Treatment Petalion Therapeutics Sn38 Treatment Of Ovarian And Colorectal Cancer

---

Home Page: starpharma.com

4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
Phone: 61 3 8532 2700

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)